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Rajotte, Desaidoi:10.1016/j.jtcvs.2005.03.021Objectives: Cryopreserved valve allografts used in congenital cardiac surgery are
associated with a significant cellular and humoral immune response. This might be
reduced by removal of antigenic cellular elements (decellularization). The aim of
this study was to determine the immunologic effect of decellularization in a rat
allograft valve model.
Methods: Brown Norway and Lewis rat aortic valves were decellularized with a
series of hypotonic and hypertonic buffers, protease inhibitors, gentle detergents
(Triton X-100), and phosphate-buffered saline. Valves were implanted into Lewis
rats in syngeneic and allogeneic combinations. Cellular (CD3 and CD8) infiltrates
were assessed with morphometric analysis, and the humoral response was assessed
with flow cytometry.
Results: Morphometric analysis identified a significant reduction in CD3 cell
infiltrates (cells per square millimeter of leaflet tissue) in decellularized allografts
compared with that seen in nondecellularized allografts at 1 (79  29 vs 3310 
223, P  .001), 2 (26  11 vs 109  20, P  .004), and 4 weeks (283  122 vs
984  145, P  .001). Anti-CD8 staining confirmed the majority of infiltrates were
cytotoxic T cells. Flow cytometric mean channel fluorescence intensity identified a
negative shift (abrogated antibody formation) for decellularized allografts compared
with nondecellularized allografts at 2 (19  1 vs 27  3, P  .033), 4 (35  2 vs
133  29, P  .001), and 16 weeks (28  2 vs 166  54, P  .017).
Conclusions: Decellularization significantly reduces the cellular and humoral im-
mune response to allograft tissue. This could prolong the durability of valve
allografts and might prevent immunologic sensitization of allograft recipients.
Allograft tissue is used extensively in congenital cardiac surgery as valvedconduits and patches to replace or reconstruct diminutive and malformedstructures. Although the cryopreserved allograft valve has acceptable re-
sults in adults, with freedom from reoperation approaching 69% at 15 years,1 failure
is much more rapid in children. Freedom from reoperation has been reported to be
as low as 69% at 48 months in children less than 2 years of age.2 It was previously
believed that this tissue was immunoprivileged. However, increasing evidence from
laboratory3,4 and clinical5,6 investigations has clearly demonstrated that this tissue is
immunogenic and stimulates an intense cell-mediated immune response. This im-
mune response has been implicated in the failure of these tissues. Equally important
is the more recent observation by our group6a and others7 that these tissues also
stimulate intense humoral responses, with panel reactive antibodies (PRA) ap-
proaching 100%. Although the evidence linking this humoral response to allograft
failure is less clear, there is concern that these preformed antibodies might compli-
cate future cardiac transplantation should it be required.8 An increased PRA level
has been associated with early development of high-grade cellular rejection and
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vasculopathy,11 and decreased survival.8,12,13
It was previously believed that preserving cellular via-
bility was essential for long-term valve durability.14 Con-
sequently, methods have been developed to prepare allo-
graft tissue with the intention of maintaining cellular
viability. However, more recent investigations have corre-
lated enhanced allograft viability with increased immuno-
genicity and increased rates of failure.15 There is increasing
evidence that the source of the alloreactive immune re-
sponse is the cellular elements of the allograft.16 These
findings, in part, have prompted the recent interest in tissue
engineering of valves, either creating valves from synthetic
matrices or through decellularization techniques to remove
the immunogenic cellular elements of the allograft tissue. It
is hypothesized that creation of an acellular matrix will
abrogate the alloreactive immune response, improving
valve durability and possibly preventing antibody forma-
tion. The purpose of this study was to investigate the cel-
lular and humoral immune response to decellularized allo-
graft tissue in a rat allograft model.
Materials and Methods
Experimental Animals
Inbred male Brown Norway (RT1.An) and Lewis (RT1.Al) rats
(weight, 175-250 g) were purchased from Charles River (Quebec)
and housed in the institutional animal care facility with food and
water ad libitum for 1 week before experimentation in accordance
with the guidelines of the Canadian Council of Animal Care.17
Surgical Technique
Aortic valve allografts were implanted into recipient animals ac-
cording to a well-established infrarenal implantation model.3,18
Briefly, this technique entails removing the aortic valve with
approximately 5 mm of ascending aorta from a donor rat and
transplanting it into the infrarenal abdominal aorta of the recipient
rat by using end-to-end anastomoses (10-0 nylon, Sharpoint) dur-
ing general anesthesia (isoflurane).
Grafts were implanted as either nondecellularized (fresh) or
decellularized grafts in both syngeneic (Lewis to Lewis) or allo-
geneic (Brown Norway to Lewis) combinations (n  6/time/
group). Nondecellularized grafts were harvested from donor ani-
mals and implanted without delay into recipient animals;
decellularized grafts were treated as described below before
implantation.
Decellularization
Tissues were decellularized by using methods similar to those
previously described by Courtman and colleagues.19 Aortic valves
were harvested from donor animals, rinsed with saline solution,
and stored in Tris buffer (pH 8.0, 50 mmol/L, on ice) for transport.
The valves were stored in CMRL solution (90 mL, Gibco), fetal
bovine serum (FBS; 10 mL, Sigma), and penicillin-streptomycin
solution (penstrep; 0.5 mL, Sigma) for 24 hours at 4°C. Samples
were placed in hypotonic Tris buffer (10 mmol/L, pH 8.0) con-
taining phenylmethylsulfonyl fluoride (0.1 mmol/L) and ethyl-
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samples were placed in 0.5% octylphenoxy polyethoxyethonal
(Triton X-100, Sigma) in a hypertonic Tris-buffered solution (50
mmol/L, pH 8.0; phenylmethylsulfonyl fluoride, 0.1 mmol/L; eth-
ylenediamine tetraacetic acid, 5 mmol/L; KCl, 1.5 mol/L) for 48
hours at 4°C. Samples were then rinsed with Sorensen’s phosphate
buffer (pH 7.3) and placed in Sorensen’s buffer containing DNase
(25 g/mL), RNase (10 g/mL), and MgCl2 (10 mmol/L) for 5
hours at 37°C. Samples were then transferred to Tris buffer (50
mmol/L, pH 9.0; Triton X-100 0.5%) for 48 hours at 4°C. Finally,
all samples were washed with phosphate-buffered saline at 4°C for
72 hours, changing the solution every 24 hours. All stages were
performed with constant stirring. Valves were stored in Hanks
balanced salt solution plus penstrep at 4°C until the time of
implantation.
The efficacy of decellularization was confirmed with staining
for overall morphology (hematoxylin and eosin), endothelial cells
(anti-CD31; sc1506, Santa Cruz Biotechnology), and interstitial
cells (anti-vimentin; MCA 862, Serotec) by the methods described
below.
Immunohistochemistry
Tissue was harvested for histology at 1, 2, and 4 weeks. Samples
were formalin fixed (10%), paraffin embedded, and serially sec-
tioned (5 m) for histologic and immunohistochemical examina-
tion, ensuring valve leaflets were visualized in all sections. Immu-
nohistochemistry involved standard staining techniques with
biotinylated secondary antibodies, a peroxidase avidin-biotin com-
plex, and 3.3= diaminobenzidene as the chromogen. Primary
monoclonal antibodies for T cells (anti-CD3; sc1127, Santa Cruz
Biotechnology) and cytotoxic T cells (anti-CD8; sc7970, Santa
Cruz Biotechnology) were used.
Tissue Analysis
Samples were examined with a light microscope, and images were
captured with a digital camera (QImaging). Morphometric analysis
was performed to measure cell counts per area (Simple PCI,
Compix). Leaflet cell density (number of labeled cells per square
millimeter) was obtained from sampling of the entire leaflet area
from representative tissue cross-sections from each animal. Cell
counts were obtained from the average cell density of 3 represen-
tative areas sampled at the 12, 4, and 8 o’clock positions from 2
representative tissue cross-sections from each animal.
Flow Cytometric Cross-Match
Serum harvest. At the time of death at 2, 4, and 16 weeks, rats
were exsanguinated, and blood was collected in 10-mL phlebot-
omy tubes (n  6/group/time point). Blood was allowed to clot,
and the tubes were centrifuged for 5 minutes at 1500 rpm. Serum
was transferred to 5-mL polypropylene tubes and stored at 86°C
until needed.
Cell isolation. Spleens were harvested from Brown Norway
rats and mechanically dissociated between sterile slides. Spleno-
cytes were isolated through repeated washing with saline, centrif-
ugation (1500 rpm 5 minutes), and red blood cell lysis (pH 7.3).
Cells were resuspended in dimethyl sulfoxide and FBS and frozen
at 86°C until needed.
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Cell number was counted in a hemocytometer with Trypan blue. Cells
(106) were washed with saline, centrifuged (1500 rpm  5 minutes),
combined with 100 L of serum from recipient rats (1:50 dilution in
FACS buffer [1% FBS in phosphate-buffered saline]) and incubated
at 37°C for 30 minutes. Cells were washed twice with FACS buffer,
centrifuged, and incubated with 100L of secondary antibody (FITC-
conjugated F[ab=]2 fragment goat anti-rat IgG, Fc fragment specific;
Jackson ImmunoResearch Laboratories Inc, Cat. No. 112-096-008,
1:200 dilution in FACS buffer) at 4°C for 30 minutes in the dark.
Cells were washed with FACS buffer, centrifuged, resuspended in
FACS buffer, and analyzed by means of flow cytometry (BD Facs-
Calibur) for mean channel fluorescence intensity, which represents
antibody binding to target cells. A rightward shift indicated the
presence of serum antibodies.
Statistical Analysis
Continuous data are expressed as means  standard error of the
Figure 1. Comparison of decellularization techniques at 200 orig-
inal magnification. Arrows indicate aortic valve leaflets. Hematox-
ylin and eosin (H&E) staining (overall morphology) and immunohis-
tochemistry for endothelial cells (anti-CD31) and interstitial cells
(anti-vimentin) are shown. Fresh (nondecellularized): note the nor-
mal laminar architecture and extensive cellularity with hematoxylin
and eosin staining. Immunohistochemistry reveals the intact endo-
thelial layer and extensive interstitial cells. Decellularized: pre-
served extracellular matrix, complete removal of the endothelial
layer, and absence of intact cellular elements. Some residual inter-
stitial cellular fragments are noted with anti-vimentin staining.mean. Analysis of variance testing was used to compare multiple
The Journal of Thoracigroups, with Scheffé post hoc analysis used to compare individual
groups. The funding organizations assumed no role in the collec-
tion of data, its analysis and interpretation, or in the right to
approve or disapprove publication of the finished manuscript.
Results
Samples of decellularized tissues are shown in Figure 1.
These images confirm the efficacy of the decellularization
process in removing the majority of cellular elements. In the
fresh (nondecellularized) tissue there was extensive cellu-
larity, an intact endothelial layer, and a laminar architecture.
In the decellularized tissue there was an absence of intact cells,
complete removal of the endothelial layer, and relative preser-
vation of the extracellular matrix. Some residual cellular frag-
ments were detected by means of vimentin staining.
Representative sections of tissue explanted at 1 week are
shown in Figure 2. Most notable in these images are the
intense T cell infiltrates and leaflet thickening in the allo-
geneic nondecellularized tissues compared with that seen in
the decellularized tissues. This difference in T cell infiltrates
was quantified by means of morphometric analysis and
summarized in Figure 3, A. Scheffé post hoc analysis con-
Figure 2. Representative immunohistochemistry for T cell in-
filtrates (CD3) 1 week after transplantation in allogeneic non-
decellularized (A), allogeneic decellularized (B), syngeneic
nondecellularized (C), and syngeneic decellularized (D) sam-
ples. Untreated allogeneic valve: early and intense T cell
infiltrate and significant thickening of the valve leaflets. This
was not present in the syngeneic model. Decellularized spec-
imens: in both the allogeneic and syngeneic models, there is a
dramatic attenuation of the immune response, as noted by
normal leaflet thickness and the absence of T cells. Arrows
indicate the location of valve leaflets adjacent to the throm-
bosis in the sinus of Valsalva. (Original magnification 400.)firmed a significant decrease in CD3 T cell infiltrates for
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logeneic nondecellularized tissue at 1 (79  29 vs 3310 
223, P  .001), 2 (26  11 vs 109  20, P  .004), and 4
weeks (283  122 vs 984  145, P  .001). There was a
modest increase in CD3 T cell infiltrates at 1 week in the
Figure 3. Decellularization reduces CD3 (A) and CD8
1, 2, and 4 weeks after transplantation. Allo ND, Allo
larized; Allo Decel, allogeneic decellularized; Syn Decsyngeneic nondecellularized group, which differed slightly
472 The Journal of Thoracic and Cardiovascular Surgery ● Augufrom that seen in the allogeneic decellularized tissues (703
 140 vs 79  29, respectively; P  .013). Otherwise, the
T cell infiltrates of the decellularized tissue were similar to
those of the control nondecellularized and decellularized
syngeneic grafts. Decellularized grafts, however, were very
) mean cell counts in leaflets of aortic valve grafts at
ic nondecellularized; Syn ND, syngeneic nondecellu-
yngeneic decellularized. (B
gene
el, sthrombogenic, as evidenced by thrombosis of the sinus of
st 2005
Meyer et al Evolving Technology
ETValsalva (Figure 2, B and D). At 16 weeks, the grafts were
completely thrombosed, with complete loss of valve leaflets
precluding meaningful analysis. Staining for cytotoxic
CD8 T cells (Figure 3, B) confirmed that the majority of
the infiltrates were cytotoxic T cells. There was a similar
decrease in CD8 T cell infiltrates in the decellularized
allograft tissue at all time points.
Flow cytometric cross-match identified a significant re-
duction in antibody production to levels that were similar to
those of syngeneic nondecellularized grafts. Representative
histograms at 16 weeks are provided in Figure 4. The
allogeneic decellularized grafts were characterized by a
leftward shift of the histogram compared with that seen in
allogeneic nondecellularized grafts, indicating the failure to
generate antibodies to decellularized allogeneic grafts. Sim-
ilar findings were noted at 2 and 4 weeks, with the former
being less pronounced. Flow cytometric mean channel flu-
orescence intensity was used to quantify these results, and
values are summarized in Figure 5. Scheffé post hoc anal-
ysis confirmed the difference between decellularized allo-
grafts and nondecellularized allografts at 2 (19  1 vs 27 
3, P  .033), 4 (35  2 vs 133  29, P  .001), and 16
Figure 4. Representative histograms for flow cytometric
allogeneic decellularized (B), syngeneic nondecellula
geneic decellularized tissue was associated with a
production compared with the nondecellularized all
curves that were nearly identical to those of syngeneweeks (28  2 vs 166  54, P  .017).
The Journal of ThoraciDiscussion
Allograft tissue is used extensively in cardiac surgery. In
adults allograft valves are used for reconstruction of the
right ventricular outflow tract in the pulmonary autograft
(Ross) procedure, and they provide an important option for
reconstruction of the aortic root, especially in cases of
endocarditis. Allograft tissue plays an even more important
role in congenital cardiac surgery, in which it is used both
as valved conduits and as patches to reconstruct congenital
abnormalities. Despite the advantages of absence of throm-
bogenicity, resistance to infection, and excellent hemody-
namics, allograft valves fail with a predictable time course,
which is particularly rapid in young children.1,2 Allograft
tissues contain living cells, at least initially.5 Thus, it is not
surprising that studies have demonstrated that these tissues
stimulate a profound cell-mediated immune response with
diffuse T cell infiltrates within 1 week of implantation in an
animal model.3,4 The progressive failure of the allograft
valve has been attributed to this alloreactive immune re-
sponse. More recently, evidence has been accumulating that
allograft tissue used in congenital cardiac surgery also stim-
ulates a profound humoral response.6a,7 The role of this
humoral response in allograft failure is less clear. However,
lysis at 16 weeks for allogeneic nondecellularized (A),
(C), and syngeneic decellularized (D) samples. Allo-
ificant leftward shift indicative of reduced antibody
eic tissue. Allogeneic nondecellularized tissue had
sues.ana
rized
sign
ogen
ic tismore concerning is the effect that the presence of preformed
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tation,8 a possibility in many children with congenital heart
disease undergoing palliative procedures, such as the Nor-
wood operation for hypoplastic left heart syndrome.
There are 2 options to attenuate this alloreactive re-
sponse: alter the host (eg, immunosuppression) or alter the
valve. Although shown to be beneficial in animal models,
currently available immunosuppression is not acceptable for
many valve candidates, especially young children, because
of toxicity. Altering the valve to reduce its immunogenicity
is another approach. As previously mentioned, it is believed
that the cellular elements are the antigenic stimulus for the
alloreactive immune response, and thus decellularization
has been proposed to reduce the antigenicity of these tis-
sues. Numerous protocols have been proposed to decellu-
larize tissues.19-22 A similar number of studies have been
performed to assess the effectiveness of removing cellular
elements and to assess the biomechanical properties of
decellularized tissues. However, there is a relative paucity
of detailed studies investigating the immunologic conse-
quences of decellularization of these tissues. Thus, the cur-
rent study used a modification of a previously described
decellularization technique19 and a well-established allo-
graft heart valve implantation model3,18 to investigate the
cellular and humoral immune response to decellularized
allograft tissues.
In the present study we clearly demonstrated that decel-
Figure 5. Decellularization reduces the humoral respon
of flow cytometric analysis at 2, 4, and 16 weeks. A
nondecellularized; Allo Decel, allogeneic decellularizlularization of aortic valve allografts reduces the aforemen-
474 The Journal of Thoracic and Cardiovascular Surgery ● Augutioned cellular immune response. Similar to previous re-
ports, allogeneic nondecellularized grafts were associated
with significant CD3 and CD8 T cell infiltrates in aortic
valve leaflets by 1 week after transplantation, rapidly de-
creasing in the following weeks.3 Decellularized grafts, on
the other hand, were associated with significant reductions
in T cell infiltrates, which were similar in density to those of
syngeneic control grafts. The explanation for the anomalous
increase in CD3 T cell infiltrates in the nondecellularized
grafts at 4 weeks is not entirely clear. This finding was not
noted in the CD8 T cells counts. Thus, it leads us to
believe that the increased CD3 T cell counts at 4 weeks
might represent infiltration of CD3 cells other than CD8
T cells, perhaps CD4 T cells. These findings are consistent
with previous work by our group and others. Legare and
colleagues3 demonstrated a nadir of infiltrates at 2 weeks in
allogeneic aortic valve transplants. Similarly, Green and
associates4 demonstrated a nadir of infiltrates in the intima
and media of aortic valve allografts at 14 days, which
rebounded somewhat at 28 days. Moreover, Green and
associates demonstrated an increased proportion of CD4 T
cells and a decreased proportion of CD8 T cells at 28 days
compared with that at 7 and 14 days.
Unfortunately, the decellularization exposed the extra-
cellular matrix, and thus the graft was highly thrombogenic.
The model used was a nonworking model, with the valve
leaflets remaining open throughout the cardiac cycle. In
decellularized allograft valves, as identified by means
D, Allogeneic nondecellularized; Syn ND, syngeneic
yn Decel, syngeneic decellularized.se to
llo N
ed; Scontrast to a working model, there is no backflow in the
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thrombosis. Whether this thrombosis would occur in a
working model is unknown. The effect of this thrombosis on
cellular infiltrates is not entirely clear. However, because
the allogeneic decellularized grafts had a paucity of T cell
infiltrates similar to that seen in syngeneic nondecellular-
ized control grafts, it could be cautiously assumed that the
effect is minimal. Moreover, the humoral response to the
allografts closely mimics the cellular data presented.
Flow cytometry demonstrated that decellularization sim-
ilarly reduces the humoral response to allograft tissue. De-
cellularization was associated with a profound reduction of
antibodies to the level of syngeneic tissues. These animal
studies are consistent with recent work in human subjects
using cryopreserved decellularized allograft tissue. Elkins
and coworkers23 recently reported that the humoral immune
response to allograft heart valves (measured by PRA) was
absent in 52 (91%) of 57 patients at 1 month and was absent
in 43 (88%) of 49 at 3 months in allograft valves treated
with the SynerGraft process for antigen reduction. Short-
term valve function was reported as satisfactory. These
findings are particularly relevant given the current research
demonstrating that allograft tissue might be sensitizing in-
fants undergoing congenital cardiac surgery,6a,7 infants who
might eventually require cardiac transplantation. Although
the tissues in the current study were valved conduits, it
could be expected that decellularization of allograft patches,
such as those used in the Norwood procedure, would have
a similarly reduced humoral immune response.
The results of this study confirm that decellularization
reduces the immunogenicity of allograft tissue. This finding
might in turn be associated with improved allograft dura-
bility. Moreover, the finding of a reduced humoral response
might prevent the sensitization that is currently seen with
allograft tissue in children, complicating subsequent trans-
plantation. However, the ultimate widespread use of such
tissue will be limited by donor availability. Others have
investigated the use of decellularized xenograft tissue, but
this has met with failure,24 presumably because of interspe-
cies extracellular matrix immunogenicity.25 Use of syn-
thetic matrices seeded with autologous cells has shown
promise,26 but they might be limited by the need to harvest,
expand, and seed autologous cells, a process that might take
14 days or greater. At present, it thus appears that decellu-
larization of allograft tissue might be the most feasible of
the 3 aforementioned options.
One of the major limitations to this study is use of a
nonfunctional model that results in sinus of Valsalva throm-
bosis. One might consider using functional models to over-
come such difficulties, including larger animal models of
pulmonary artery implants or a recently described func-
tional rat model with aortic insufficiency.27 The current
issue of thrombosis makes it difficult to speculate on the
The Journal of Thoracieffect the reduced cellular infiltrates will have on long-term
durability. However, because the cellular infiltrates have
been correlated with reduced valve durability, it could be
expected that durability would be improved. In addition,
longer-term studies are required to investigate the capacity
for the matrix to repopulate with host endothelial and inter-
stitial cells. Because it could be expected that many of these
decellularized allografts would be stored with cryopreser-
vation, the effect of cryopreservation on an acellular matrix
requires careful assessment. However, in this experiment
we wanted to limit the number of variables that would
confound our interpretation of the effects of decellulariza-
tion. In previous work with the same rodent model, our
group had demonstrated that cryopreservation is associated
with a lack of protection from allorecognition, increased
valve leaflet injury, and increased cellular infiltrates, even in
a syngeneic model.28 Finally, work is required to ensure the
integrity of the decellularized graft and the individual com-
ponents of the extracellular matrix (eg, glycosaminogly-
cans), which might be essential for repopulation of the graft
by host cells.
In summary, we have demonstrated that decellularization
of aortic valve allografts is associated with a significant
reduction in cellular and humoral immune responses to
levels seen with nonimmunogenic syngeneic tissue. These
findings suggest that the acellular matrix might provide a
suitable environment for repopulation by host cells (eg,
fibroblasts), which would provide the extracellular matrix
with a regenerative capacity typical of native valves, thus
improving allograft durability. Moreover, the reduced hu-
moral response might prevent sensitization of recipients of
allograft tissue. This would have enormous implications for
the survival and quality of life of all valve recipients,
especially children. Ongoing studies in a larger animal
model of orthotopic implantation will provide information
on the thrombogenicity, functional integrity, and capacity
for repopulation by host cells.
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